Article 1 to 2 out of 2 for "Dr. Thomas von Rüden"
Ordered by
DIREVO announces validation of bestMab (08 May 2008) New approach for the optimization of therapeutic antibodies generates optiMIRA, an enhanced version of Adalimumab (Humira) to significantly enhance antibody drug development," said Dr. ThomasvonRüden, CEO...
Direvo Acquires AC Biotec (07 Nov 2007) and processes", stated Dr. ThomasvonRüden, CEO of Direvo. "This will also help... subsidiary of Direvo Biotech with Dr. Simon Curvers continuing as Managing...
Top